EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer

Margherita Ambrosini, Claire Gallois, Annalice Gandini, Aurélie Lecanu, Emily Alouani, Filippo Pietrantonio, Francesca Bergamo, Chiara Cremolini, Thibault Mazard, David Tougeron, Rosine Guimbaud, Sara Lonardi und 5 weitere

European Journal of Cancer · 2026-05 · 239 · 116731

DOI: 10.1016/j.ejca.2026.116731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-05. Verfasst von Margherita Ambrosini und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, AP-HP, Paris, France; Department of Medical Oncology, Fond…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, CTLA-4 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INCa, Association pour la Recherche sur le Cancer, Fondation ARC pour la Recherche sur Le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Around 15-50% of patients with dMMR/MSI-H metastatic colorectal cancer (mCRC) experience primary and secondary resistance to immune checkpoint inhibitors (ICI). We previously described three transcriptomic clusters (A, B, C) linked to progression-free survival (PFS), with cluster A ("StromalHIGH - ProliferationLOW") associated with the shortest PFS. Here we combine gene signature and mucinous phenotype to predict the benefit from anti-CTLA-4 plus anti-PD-1. METHODS: We used 3'RNA-sequencing data from pre-treatment samples of two independent cohorts of patients with dMMR/MSI-H mCRC treated with anti-PD-1 ±anti-LAG-3 ("Mono") or anti-PD-1 +anti-CTLA-4 ("Combo"). A rank-based k-Top Scoring Pairs (k-TSP) classifier was trained in Cohort 1 (103 patients) to predict assignment to Cluster A versus B/C and validated in Cohort 2 (87 patients). Patients receiving an anti-PD-L1 and with ECOG ≥ 2 were excluded. We defined a composite stratum crossing Clusterk-TSP (A vs B/C) with mucinous component (present vs absent). RESULTS: Cluster A was enriched for mucinous tumors and had shorter PFS in both cohorts. The k-TSP selected four gene pairs predictive of Cluster A (YPEL2 >H2AZ1, H6PD>COX7A2, STAT5B>SNRPE, ZHX3 >TRAPPC4) and was validated in Cohort 2 with 68.1% balanced accuracy. In the pooled population (163 patients), the composite stratum × treatment interaction improved model fit (likelihood-ratio p ≈ 0.04). Patients with Clusterk-TSP A + mucinous (25/163, 15.3%) derived advantage from Combo versus Mono: adjusted 24-month PFS 72.2% vs 13.8% (HR 0.10, 95% CI 0.02-0.39; p < 0.001). CONCLUSIONS: An 8-Gene signature combined with mucinous component identifies a subgroup that preferentially benefits from anti-PD-1 +CTLA-4, warranting prospective validation to guide regimen selection in dMMR/MSI-H mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCTLA-4 AntigenAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorTranscriptomeHumansFemaleMicrosatellite InstabilityMaleGene Expression ProfilingAgedMiddle Aged

Stichwörter der Autor:innen

Anti-CTLA-4Colorectal cancerGene signatureImmune checkpoint inhibitorsMicrosatellite instabilityMucinous component

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCTLA-4 AntigenBiomarkers, TumorCTLA4 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, AP-HP, Paris, France; Department of Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, AP-HP, Paris, France; Centre de Recherche des Cordeliers, INSERM, CNRS, Université Paris Cité, Sorbonne Université, USPC, Equipe…
  • Centre de Recherche des Cordeliers, INSERM, CNRS, Université Paris Cité, Sorbonne Université, USPC, Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
  • Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital of Tours, Tours University, U1069 INSERM "Nutrition, Croissance et Cancer", Tours, France.
  • Digestive Oncology Department, Rangueil Hospital, University Hospital of Toulouse, Toulouse, France.
  • Department of Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.

Förderung

  • INCa
  • Association pour la Recherche sur le Cancer
  • Fondation ARC pour la Recherche sur Le Cancer

Zitieren

APA

Ambrosini, M., Gallois, C., Gandini, A., Lecanu, A., Alouani, E., Pietrantonio, F., Bergamo, F., Cremolini, C., Mazard, T., Tougeron, D., Guimbaud, R., Lonardi, S., Selves, J., Mouillet-Richard, S., Emile, J. F., Taieb, J., & Laurent-Puig, P. (2026). From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer. European Journal of Cancer, 239, 116731. https://doi.org/10.1016/j.ejca.2026.116731

Vancouver

Ambrosini M, Gallois C, Gandini A, Lecanu A, Alouani E, Pietrantonio F, et al. From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer. European Journal of Cancer. 2026;239:116731. doi:10.1016/j.ejca.2026.116731

BibTeX
@article{Ambrosini2026,
  author = {Ambrosini, Margherita and Gallois, Claire and Gandini, Annalice and Lecanu, Aurélie and Alouani, Emily and Pietrantonio, Filippo and Bergamo, Francesca and Cremolini, Chiara and Mazard, Thibault and Tougeron, David and Guimbaud, Rosine and Lonardi, Sara and Selves, Janick and Mouillet-Richard, Sophie and Emile, Jean-Francois and Taieb, Julien and Laurent-Puig, Pierre},
  title = {From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {239},
  pages = {116731},
  doi = {10.1016/j.ejca.2026.116731}
}
Kostenlos starten →